Top Story

Data support predictive significance of superficial vein thrombosis

March 2, 2015

Researchers found that a history of superficial vein thrombosis may be predictive of venous and arterial thrombotic events and these findings may play an important role in clinical decision making regarding anticoagulation, according to a recent study in Blood.

“It is essential that clinicians realize the severity of superficial vein thrombosis, both in the acute phase and in the long run. In the former situation, anticoagulant treatment probably prevents serious complications such as deep vein thrombosis and pulmonary embolism; for the latter, patients with a history of [superficial vein thrombosis] will need to receive strict anticoagulant prophylaxis when they encounter a high-risk situation for venous thromboembolism (eg, surgery or plaster cast),” Suzanne C. Cannegieter, MD, PhD, of the department of clinical epidemiology, Leiden University Medical Centre, Leiden, The Netherlands, told HemOnc Today.

FDA NewsDrug Pipeline

FDA grants orphan drug designation to Reolysin for fallopian tube cancer

March 2, 2015
The FDA today granted orphan drug designation to pelareorep for the treatment of fallopian tube cancer, according to a press release from the drug’s…
FDA NewsDrug Pipeline

FDA grants 'breakthrough' status to EBV-CTL for EBV-associated lymphoproliferative disease

March 2, 2015
The FDA today granted breakthrough therapy designation to EBV-CTL for the treatment of patients with rituximab-refractory, Epstein-Barr virus-associated…
Meeting News Coverage

HIV did not affect HCC recurrence or survival after LT

March 2, 2015
Survival and recurrence rates were unaffected by HIV infection among patients who underwent liver transplantation for hepatocellular carcinoma, according to a poster…
Industry News

Novartis completes acquisition of GSK oncology portfolio

March 2, 2015
Novartis completed its acquisition of GlaxoSmithKline’s oncology portfolio for an aggregate cash consideration of $16 billion, the companies announced…
More News Headlines »
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
thumbnail for video 4040847621001

MET targeting, PD-L1/PD-1 inhibition highlight recent developments in genitourinary oncology

February 11, 2015
Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, president of Levine Cancer Institute at Carolinas HealthCare System and…
More »
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
morganatic-roan morganatic-roan